If I’d invested £1k in CRISPR Therapeutics shares on January 3, here’s what I’d have now!

This could be the most exciting growth stock out there. Dr James Fox takes a closer look at CRISPR Therapeutics shares after the recent rally.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Silhouette of a bull standing on top of a landscape with the sun setting behind it

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

CRISPR Therapeutics (NASDAQ:CRSP) shares were recently dumped by star-stock picker Cathie Wood. So, does this mean its bull run is over? I don’t think so. Let’s take a closer look at recent performance and explore why I think investors should consider CRISPR.

What is it?

The business is a clinical-stage biotech company that’s using the CRISPR-Cas9 gene editing system to create treatments for hereditary hematologic disorders, cancers, and even diabetes.

Like many growth stocks, it’s been on a bumpy ride over the last few years. In 2021, the share price reached a phenomenal $210 before falling. But as we know, this was a period of speculative investment during which many growth-oriented companies achieved unsustainable valuations.

In 2023, CRISPR began the year with a valuation reflecting the company’s position — a highly promising biotech without a regulator-approved treatment. But since January 3 — the first day of trading this year — the stock has just 65%.

So, if I’d invested £1,000 in it on that day, then today I’d have around £1,650. Well almost. The pound has appreciated around 2% against the dollar. I’d actually have a little less than that.

The share price kicked forward in April after the company and partner Vertex submitted their CRISPR-based ex vivo cell therapy exagamglogene autotemcel (exa-cel) for FDA approval, for sickle cell disease (SCD) and beta thalassemia.

Why so promising?

Why did Wood sell?

Firstly, it’s important to note that Wood had been topping up her position in April. And her ARK portfolio still has a sizeable position in the company even after the sales. The biotech makes up around 3.4% of Wood’s ARK ETF and its stake it still worth worth $423.9m.

So, it may be the case that Wood was cashing in on short-term gains. It certainly doesn’t look like she’s lost faith in the firm.

If exa-cel receives FDA approval, then it would mark a major milestone — the company’s first approved treatment. Analysts are already suggesting the functional cure could bring in an average of $264.8m in sales during 2024.

Obviously, there’s no guarantee that the treatment will be approved. But trial data was positive —  of 44 patients, 42 were “functionally cured” of their disease — and support appears to be growing for the gene-editing therapies.

Traditionally, only one out of 10 drug candidates successfully passes clinical trial testing and regulatory approval. So, it’s worth noting that CRISPR has a pipeline of 22 other treatments. Many will fail, but some, I’m hopeful, will reach the market. It also has $2bn in cash to aid development.

CRISPR Therapeutics Pipeline

I bought some of the shares earlier in the year. And I’m fortunate they’re doing rather well despite a strengthening pound. It’s always hard to put a valuation on companies at this stage of their development, but I’m positive about the potential of this gene-editing firm. Although I’m low on capital so won’t buy more for now, I still think there’s value at $65.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has positions in CRISPR Therapeutics. The Motley Fool UK has recommended CRISPR Therapeutics. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will it be too late to buy Nvidia stock in March?

NVIDIA stock is up more than 60% since the start of 2024. Our writer considers whether it might still be…

Read more »

Typical street lined with terraced houses and parked cars
Investing Articles

Why did Direct Line shares just soar 27%?

Direct Line shares have jumped more than a quarter in the course of today's trading session. Our writer explains why…

Read more »

Close-up of British bank notes
Investing Articles

These 2 shares are Dividend Aristocrats. Which should I buy this March?

Our writer likes the business model of this pair of FTSE 100 Dividend Aristocrats. So why would he only consider…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

I bought 49 Unilever shares in June. Here’s what they’re worth today

Harvey Jones bought a modest amount of Unilever shares last summer hoping the stock would soon recover. He's having to…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

I reckon these shares, potentially 20% undervalued, are Warren Buffett’s type of investment

Oliver Rodzianko thinks Games Workshop is an absolutely stellar investment. As it's potentially undervalued, he reckons Warren Buffett would agree.

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Great investing habits that can boost my Stocks and Shares ISA

Forget complicated calculations and financial jargon! Our writer uses a few simple habits to build wealth inside his Stocks and…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Why has the St. James’s Place share price crashed 30%, after FY results?

The St. James's Place share price has just fallen off a cliff. What could have gone wrong in 2023 that's…

Read more »

Family in protective face masks in airport
Investing Articles

Here’s how much I’d have if I’d bought 1,000 Rolls-Royce shares 10 years ago

Rolls-Royce shares may be flying high this year but that wasn't always the case. I'm calculating how much I'd have…

Read more »